Bio-Rad Laboratories Inc (BIO)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 488,100 | 411,753 | 407,297 | 433,331 | 403,966 | 457,850 | 390,001 | 464,136 | 434,215 | 517,943 | 596,584 | 802,316 | 470,783 | 859,902 | 732,836 | 673,470 | 662,205 | 840,325 | 607,584 | 603,551 |
| Short-term investments | US$ in thousands | 1,176,400 | 1,212,080 | 1,214,750 | 1,217,950 | 1,208,890 | 1,306,700 | 1,338,240 | 1,392,880 | 1,362,020 | 1,337,740 | 1,376,640 | 1,276,720 | 404,695 | 482,756 | 434,122 | 351,958 | 334,473 | 319,662 | 429,786 | 438,710 |
| Total current liabilities | US$ in thousands | 467,800 | 497,943 | 486,961 | 466,154 | 522,799 | 558,176 | 581,982 | 589,623 | 568,708 | 570,677 | 613,714 | 648,331 | 680,938 | 649,916 | 587,052 | 609,892 | 631,536 | 986,657 | 926,895 | 869,254 |
| Cash ratio | 3.56 | 3.26 | 3.33 | 3.54 | 3.09 | 3.16 | 2.97 | 3.15 | 3.16 | 3.25 | 3.22 | 3.21 | 1.29 | 2.07 | 1.99 | 1.68 | 1.58 | 1.18 | 1.12 | 1.20 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($488,100K
+ $1,176,400K)
÷ $467,800K
= 3.56
The cash ratio of Bio-Rad Laboratories Inc has shown an upward trend from March 31, 2020, to December 31, 2024. The cash ratio measures the company's ability to cover its short-term obligations using only its cash and cash equivalents.
From the data provided, we observe that the cash ratio increased steadily from 1.20 on March 31, 2020, to 3.56 on December 31, 2024. This indicates that the company has significantly improved its liquidity position over the period under review, reflecting a strengthening ability to meet its short-term liabilities with its cash reserves.
The company experienced fluctuations in the cash ratio during the period, reaching a peak of 3.56 on December 31, 2024, and a low of 1.12 on June 30, 2020. These fluctuations may be due to various factors such as changes in operating cash flows, investments in liquid assets, or changes in short-term liabilities.
Overall, the increasing trend in the cash ratio suggests that Bio-Rad Laboratories Inc has been effective in managing its cash resources and maintaining a healthy liquidity position to meet its short-term obligations. Investors and creditors may view this positively as it indicates the company's ability to withstand financial challenges and capitalize on opportunities that may arise.
Peer comparison
Dec 31, 2024